. 2015 Feb 3;70(6):1751–1756. doi: 10.1093/jac/dkv006

Table 2.

MICs of SMT19969, fidaxomicin, metronidazole and vancomycin for 82 C. difficile clinical isolates

Panel (n)	Agent	MIC range (mg/L)	MIC₅₀ (mg/L)	MIC₉₀ (mg/L)
Genotypically distinct (30)^a	SMT19969	0.06–0.125	0.125	0.125
	vancomycin	1–4	2	2
	metronidazole	0.25–2	0.5	2
	fidaxomicin	0.008–0.125	0.03	0.06
Ribotype 001 (10)	SMT19969	0.06–0.125	0.125	0.125
	vancomycin	0.5–4	1	4
	metronidazole	0.125–1	1	1
	fidaxomicin	0.008–0.06	0.03	0.06
Ribotype 027 (11)	SMT19969	0.125–0.25	0.125	0.125
	vancomycin	0.5–4	1	2
	metronidazole	1–2	2	2
	fidaxomicin	0.03–0.06	0.06	0.06
Ribotype 106 (10)	SMT19969	0.125–0.25	0.125	0.125
	vancomycin	0.5–4	1	2
	metronidazole	1–2	2	2
	fidaxomicin	0.03–0.125	0.06	0.125
Reduced metronidazole susceptibility (21)^b	SMT19969	0.06–0.125	0.125	0.125
	vancomycin	0.5–4	1	2
	metronidazole	4–8	4	8
	fidaxomicin	0.015–0.03	0.03	0.03
Overall total (82)	SMT19969	0.06–0.25	0.125	0.125
	vancomycin	0.5–4	1	2
	metronidazole	0.125–8	2	8
	fidaxomicin	0.008–0.125	0.03	0.06

^aThirty distinct isolates of different PCR ribotype.

^bRibotype 001.